港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

九源基因

6.090

+0.000

成交量：5.54萬

成交額：33.71萬

市值：14.92億

市盈率：8.35

高：6.100

開：6.090

低：6.040

收：6.090

資料載入中...

總覽公司新聞資訊公告

金十數據整理：1月1日歐盤美盤重要新聞彙總

九源基因回應司美格魯肽大規格申報受挫：意料之中，不會影響藥物註冊進度

首個國產司美格魯肽上市申請未獲通過

首個國產司美格魯肽上市申請未獲批准九源基因上市即破發

深圳商报·读创

首個國產司美格魯肽上市申請未獲批准

減肥神藥漸成苦海，九源基因泛起愛恨

九源基因(02566)股價上升5.185%，現價港幣$7.1

阿斯达克财经

九源基因(02566)上漲5.13%，報7.79元/股

港股異動 | 九源基因(02566)盤中跌超5%再創新低較招股價已跌40% 總市值不足20億港元

九源基因(02566)股價下跌5.155%，現價港幣$7.36

阿斯达克财经

醫健IPO解碼丨押寶“減肥神藥”，九源基因赴港上市前景幾何？

21世纪经济报道

“減肥神藥”司美格魯肽國內上市熱潮下，押注國產平替的九源基因為何二級市場“遇冷”？

【IPO月報】11月港股IPO市場維持活躍晶科電子股份超購倍數位列港史第二

九源基因12月04日遭主力拋售126萬元環比增加193.02%

九源基因12月03日主力資金流出43萬元連續3日減倉

公司熱點 | 手握中國首款司美格魯肽生物類似藥，九源基因上市即破發，生物製藥公司不香了嗎？

九源基因在港交所上市：市值約19億港元，相對縮水約38%

九源基因在港交所上市，華東醫藥為最大股東

九源基因(02566)股價上升8.105%，現價港幣$8.27

阿斯达克财经

異動解讀 | 九源基因上市首日破發大跌38%,股價或受"減肥神藥"概念炒作影響

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02566/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02566","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":6.09,"timestamp":1746778087016,"preClose":6.09,"halted":0,"volume":55400,"delay":0,"floatShares":109000000,"shares":245000000,"eps":0.7291073809653457,"marketStatus":"休市中","change":0,"latestTime":"05-09 16:08:07","open":6.09,"high":6.1,"low":6.04,"amount":337102,"amplitude":0.009852,"askPrice":6.09,"askSize":59000,"bidPrice":6.02,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.7291073809653457,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":6.09,"dividendRate":0.009788,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0.9578146626245387,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","floatShares":109000000,"roa":"6.08%","roe":"11.47%","lyrEps":0.729107,"volumeRatio":0.9578146626245387,"shares":245000000,"dividePrice":0.060163,"high":6.1,"amplitude":0.009852,"preClose":6.09,"low":6.04,"week52Low":5.18,"pbRate":"0.91","psRate":"1.01","week52High":9.1,"institutionHeld":0,"latestPrice":6.09,"committee":-0.966667,"eps":0.7291073809653457,"divideRate":0.009788,"volume":55400,"delay":0,"ttmEps":0.7291073809653457,"open":6.09,"prevYearClose":6.6,"prevWeekClose":5.98,"prevMonthClose":5.95,"prevQuarterClose":6.78,"fiveDayClose":5.95,"twentyDayClose":5.59,"sixtyDayClose":6.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02566\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500104938","title":"金十數據整理：1月1日歐盤美盤重要新聞彙總","url":"https://stock-news.laohu8.com/highlight/detail?id=2500104938","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500104938?lang=zh_tw&edition=fundamental","pubTime":"2025-01-01 23:01","pubTimestamp":1735743693,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4504","LU0348816934.USD","LU1282648689.USD","LU0918141705.HKD","BK4220","BK4554","LU0880133367.SGD","06808","DGAZ","LU0501845795.SGD","LU1152091168.USD","BK4585","BK4579","LU0797268264.HKD","BK4548","02566","IE00B0JY6N72.USD","LU0251143458.SGD","ZBmain","BK4502","LU0651946864.USD","BABA","BK4524","LU0067412154.USD","LU0072913022.USD","LU1688375341.USD","ZNmain","ZFmain","BK4588","BK4533","BK4565","NGmain","09988","LU0128525689.USD","TNmain","QGmain","LU1046422090.SGD","BK4534","BK1501","ZTmain","UNG","LU0310800965.SGD","LU1823568750.SGD","BK4527","BK4581","UGAZ","BK4558","LU1515016050.SGD","LU1046421795.USD","UBmain"],"gpt_icon":0},{"id":"2500984867","title":"九源基因回應司美格魯肽大規格申報受挫：意料之中，不會影響藥物註冊進度","url":"https://stock-news.laohu8.com/highlight/detail?id=2500984867","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500984867?lang=zh_tw&edition=fundamental","pubTime":"2025-01-01 20:56","pubTimestamp":1735736185,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02566"],"gpt_icon":0},{"id":"2495690893","title":"首個國產司美格魯肽上市申請未獲通過","url":"https://stock-news.laohu8.com/highlight/detail?id=2495690893","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495690893?lang=zh_tw&edition=fundamental","pubTime":"2024-12-31 20:54","pubTimestamp":1735649653,"startTime":"0","endTime":"0","summary":"12月31日，国家药品监督管理局的药品通知件送达信息显示，九源基因（02566.HK）的司美格鲁肽注射液在列。这意味着该药品上市申请暂时未能通过。2024年4月2日，九源基因递交了司美格鲁肽注射液的上市申请并获受理，适应证为用于成人2型糖尿病血糖控制。这是国内第一家申报上市的司美格鲁肽生物类似药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412313284249627.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412313284249627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02566"],"gpt_icon":0},{"id":"2495738696","title":"首個國產司美格魯肽上市申請未獲批准 九源基因上市即破發","url":"https://stock-news.laohu8.com/highlight/detail?id=2495738696","media":"深圳商报·读创","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495738696?lang=zh_tw&edition=fundamental","pubTime":"2024-12-31 19:28","pubTimestamp":1735644516,"startTime":"0","endTime":"0","summary":"国家药监局12月31日最新药品通知件送达信息显示：九源基因的司美格鲁肽注射液在列，意味着该产品暂时未获批准。今年4月2日，九源基因递交了司美格鲁肽注射液的上市申请并获受理，这也是国内第一家申报上市的司美格鲁肽生物类似药。然而，备受期待的生物制药公司九源基因此前遭遇了上市即破发的尴尬局面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412313284208063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02566"],"gpt_icon":0},{"id":"2495667364","title":"首個國產司美格魯肽上市申請未獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2495667364","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495667364?lang=zh_tw&edition=fundamental","pubTime":"2024-12-31 18:25","pubTimestamp":1735640706,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02566"],"gpt_icon":0},{"id":"2492110074","title":"減肥神藥漸成苦海，九源基因泛起愛恨","url":"https://stock-news.laohu8.com/highlight/detail?id=2492110074","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492110074?lang=zh_tw&edition=fundamental","pubTime":"2024-12-19 15:41","pubTimestamp":1734594060,"startTime":"0","endTime":"0","summary":"但不可否认的是，九源基因的业务基本面中，如今并未有太多闪光点。2021 年，九源基因在国内第一家获得司美格鲁肽生物类似药临床默示许可，2023 年率先完成临床 III 期研究，此次又在国内第一家提交司美格鲁肽生物类似药用于2型糖尿病适应症的上市申请。由此可见，李邦良无论是在华东医药还是九源基因都有着显著的影响力。业务方面，九源基因与华东医药同样存在诸多交集。九源基因负责研发和生产，华东医药负责销售推广。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219155035ab83dfcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219155035ab83dfcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":0},{"id":"2492944444","title":"九源基因(02566)股價上升5.185%，現價港幣$7.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2492944444","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492944444?lang=zh_tw&edition=fundamental","pubTime":"2024-12-18 10:10","pubTimestamp":1734487800,"startTime":"0","endTime":"0","summary":"[上升股]九源基因(02566) 股价在上午10:10比前收市价上升5.185%，现股价为港币$7.1。至目前为止，今日最高价为$7.1，而最低价为$6.72。总成交量为24.74万股，总成交金额为港币$171.057万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241218748/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02566"],"gpt_icon":0},{"id":"2490476885","title":"九源基因(02566)上漲5.13%，報7.79元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490476885","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490476885?lang=zh_tw&edition=fundamental","pubTime":"2024-12-11 14:10","pubTimestamp":1733897448,"startTime":"0","endTime":"0","summary":"12月11日，九源基因(02566)盘中上涨5.13%，截至14:10，报7.79元/股，成交377.99万元。杭州九源基因工程股份有限公司主营业务为生物药品及医疗器械的研发、生产和商业化，专注于骨科、代谢疾病、肿瘤及血液四大治疗领域。根据相关资料，这四个领域预计在不久的将来将持续占据中国药物总销售额的51.5%，大大超过中国医药行业的整体表现。截至2024年中报，九源基因营业总收入7.02亿元、净利润1.05亿元。\n\n\r\n            责任编辑：磐石","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/11141046249426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02566"],"gpt_icon":0},{"id":"2490305797","title":"港股異動 | 九源基因(02566)盤中跌超5%再創新低 較招股價已跌40% 總市值不足20億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490305797","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490305797?lang=zh_tw&edition=fundamental","pubTime":"2024-12-10 14:34","pubTimestamp":1733812485,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，九源基因盘中跌超5%，低见7.36港元，再创上市新低，较招股价12.42港元已跌超40%。截至发稿，跌4.38%，报7.42港元，成交额1465.85万港元，总市值已不足20亿港元。据悉，九源基因于11月28日挂牌上市，当日一开盘该股票价格便暴跌至7.5港元，跌幅达到39.61%。全天收市7.65港元，换手率高达26.54%。因公开发售部分申购倍数超过100倍，触发回拨机制，九源基因将1815.94万股股份，由国际发售回拨至公开发售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566"],"gpt_icon":0},{"id":"2490321710","title":"九源基因(02566)股價下跌5.155%，現價港幣$7.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2490321710","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490321710?lang=zh_tw&edition=fundamental","pubTime":"2024-12-10 10:05","pubTimestamp":1733796300,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在上午10:05比前收市价下跌5.155%，现股价为港币$7.36。至目前为止，今日最高价为$7.98，而最低价为$7.36。总成交量为92.68万股，总成交金额为港币$707.588万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD241210551/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02566"],"gpt_icon":0},{"id":"2490120217","title":"醫健IPO解碼丨押寶“減肥神藥”，九源基因赴港上市前景幾何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2490120217","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490120217?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 15:27","pubTimestamp":1733729220,"startTime":"0","endTime":"0","summary":"九源基因的收入主要来自骨科、肿瘤、血液三大板块。此外根据招股书披露，九源基因的毛利率同样出现了下跌。截至最后可行日期，九源基因已围绕上述四大治疗领域建立了多元化的产品组合，当中包括8款已上市产品，以及超过10款在研产品。押宝“减肥神药”为了开拓新的营收点，九源基因目前正在研发司美格鲁肽仿制药JY29-2，目前该药品有两款，分别以吉优泰、吉可亲作为品牌名称用于治疗2型糖尿病和肥胖症及超重。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-12-09/doc-incyvxpt5938115.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-09/doc-incyvxpt5938115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02566"],"gpt_icon":0},{"id":"2489274246","title":"“減肥神藥”司美格魯肽國內上市熱潮下，押注國產平替的九源基因為何二級市場“遇冷”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2489274246","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489274246?lang=zh_tw&edition=fundamental","pubTime":"2024-12-07 17:46","pubTimestamp":1733564760,"startTime":"0","endTime":"0","summary":"　　减重版司美格鲁肽正式在国内上市之际，头顶该款“减肥神药”概念的二级市场“新秀”却遭遇了一股寒流。针对产品布局等相关问题，记者致函采访九源基因，截至发稿未收到回复。　　目前，九源基因的司美格鲁肽注射液“吉优泰”的上市申请已于今年4月率先获得受理，而用于治疗肥胖症及超重的产品“吉可亲”刚刚于今年1月获批临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-07/doc-incyrrrn7724258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02566"],"gpt_icon":0},{"id":"2489425399","title":"【IPO月報】11月港股IPO市場維持活躍 晶科電子股份超購倍數位列港史第二","url":"https://stock-news.laohu8.com/highlight/detail?id=2489425399","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489425399?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 10:13","pubTimestamp":1733451209,"startTime":"0","endTime":"0","summary":"金吾财讯 | 进入11月，香港IPO市场持续保持活跃态势，本月共有7家企业成功登陆港交所主板，涵盖珠宝、生物科技、电子制造等多个行业领域。本月的认购情绪高涨，其中晶科电子股份的申购热度空前高涨，九源基因紧跟其后。随着政策层面的支持力度不断加大及市场环境逐步改善，预计港股IPO市场将持续保持良好发展势头。同时，“港股年内第二大IPO”的称号也使其有望收入囊中。","market":"sg","thumbnail":"https://static.szfiu.com/news/20220324/YTNhZjA5ZTE4MjQwNDU0MzY1MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YTNhZjA5ZTE4MjQwNDU0MzY1MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949113","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02519","BK1151","HSCEI","02582","02566","BK1103","BK1183","07226","02585","02510","06936","YANG","HSTECH","02551"],"gpt_icon":0},{"id":"2488343159","title":"九源基因12月04日遭主力拋售126萬元 環比增加193.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488343159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488343159?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 16:17","pubTimestamp":1733300222,"startTime":"0","endTime":"0","summary":"12月04日, 九源基因股价跌3.16%，报收7.98元，成交金额1135万元，换手率1.29%，振幅4.37%，量比0.00。九源基因今日主力资金净流出126万元，连续4日净流出，上一交易日主力净流出43万元，今日环比增加193.02%。该股近5个交易日下跌35.67%，主力资金累计净流出367万元，其中3个交易日为股价上涨时净流出；近20日主力资金累计净流出367万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204161748abf5016a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204161748abf5016a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":1},{"id":"2488602129","title":"九源基因12月03日主力資金流出43萬元 連續3日減倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2488602129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488602129?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 16:15","pubTimestamp":1733213755,"startTime":"0","endTime":"0","summary":"12月03日, 九源基因股价涨0.73%，报收8.24元，成交金额1241万元，换手率1.37%，振幅3.30%，量比0.00。九源基因今日主力资金净流出43万元，连续3日净流出，上一交易日主力净流出25万元，今日环比增加72.00%。该股近5个交易日下跌33.66%，主力资金累计净流出241万元，其中3个交易日为股价上涨时净流出；近20日主力资金累计净流出241万元，其中净流出天数为3日。该股主力净额占比0.05%，港股市场排名2582/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203161632a268c1e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203161632a268c1e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":1},{"id":"2487579781","title":"公司熱點 | 手握中國首款司美格魯肽生物類似藥，九源基因上市即破發，生物製藥公司不香了嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2487579781","media":"读创财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487579781?lang=zh_tw&edition=fundamental","pubTime":"2024-11-30 20:33","pubTimestamp":1732969980,"startTime":"0","endTime":"0","summary":"备受期待的生物制药公司九源基因遭遇了上市即破发的尴尬局面。8款已上市产品包括骨科、肿瘤、血液领域的1款创新药械组合，2款生物制品、5款化学药品。JY29-2（吉优泰）是中国首款取得IND批准、完成III期临床试验并递交NDA申请的司美格鲁肽生物类似药；针对肥胖症及超重适应症的III期临床试验于2024年10月开展，同时正在研发用于治疗肥胖症及超重的司美格鲁肽口服片剂。九源基因全球发售4539.88万股股份，公开和国际发售各占50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130203929a26192b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130203929a26192b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":1},{"id":"2487545656","title":"九源基因在港交所上市：市值約19億港元，相對縮水約38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487545656","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487545656?lang=zh_tw&edition=fundamental","pubTime":"2024-11-30 10:17","pubTimestamp":1732933046,"startTime":"0","endTime":"0","summary":"11月28日，杭州九源基因工程股份有限公司在港交所上市。本次上市，九源基因的发行价为12.42港元/股，发行数量为4539.88万股H股，另有约15%超额配股权。假设超额配股权未获行使，九源基因的募资总额约为5.64亿港元，扣除发行费用7844万港元，募资净额约为4.85亿港元。天眼查App信息显示，九源基因成立于1993年12月。截至最后可行日期，九源基因已围绕上述四大治疗领域建立了多元化的产品组合，当中包括8款已上市产品，以及超过10款在研产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130104556abea28ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130104556abea28ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":1},{"id":"2487519770","title":"九源基因在港交所上市，華東醫藥為最大股東","url":"https://stock-news.laohu8.com/highlight/detail?id=2487519770","media":"药渡","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487519770?lang=zh_tw&edition=fundamental","pubTime":"2024-11-30 07:30","pubTimestamp":1732923036,"startTime":"0","endTime":"0","summary":"11月28日，九源基因在港交所正式上市，共发行4539.88万股。经股权结构层层剥茧后发现，九源基因与华东医药紧密相连。李邦良为九源基因的创始人，也是华东医药的前董事长。实力选手登场与未盈利的Biotech不同，九源基因此次在港交所上市并为带“B”，因其已是较为成熟的中型药企。首款在中国获批的利拉鲁肽生物类似药“利鲁平”便是来自九源基因，只不过在2017年及2019年，利鲁平被转让给了华东医药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130073704abe9d7a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241130073704abe9d7a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566"],"gpt_icon":1},{"id":"2487374378","title":"九源基因(02566)股價上升8.105%，現價港幣$8.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2487374378","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487374378?lang=zh_tw&edition=fundamental","pubTime":"2024-11-29 09:50","pubTimestamp":1732845000,"startTime":"0","endTime":"0","summary":"[上升股]九源基因(02566) 股价在上午09:50比前收市价上升8.105%，现股价为港币$8.27。至目前为止，今日最高价为$8.27，而最低价为$7.71。总成交量为128.64万股，总成交金额为港币$1.025千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241129271/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02566"],"gpt_icon":0},{"id":"1115340126","title":"異動解讀 | 九源基因上市首日破發大跌38%,股價或受\"減肥神藥\"概念炒作影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1115340126","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115340126?lang=zh_tw&edition=fundamental","pubTime":"2024-11-29 09:36","pubTimestamp":1732844191,"startTime":"0","endTime":"0","summary":"今日,九源基因(02566)在港交所挂牌上市,股价一度大涨后出现大幅回落,最终收盘跌5.23%,报7.65港元。\n\n九源基因是一家专注于骨科、代谢疾病、肿瘤及血液四大治疗领域的生物医药公司,公开招股时被市场炒作为\"减肥神药\"概念。由于此前募资时公众认购热情高涨,认购倍数高达676倍,股价一度大涨后但无法持续,或因投资者对其\"减肥神药\"概念预期过高,在现实面前难以持守,出现大幅回落。\n\n同时,九源基因还吸引了阿里健康、复星实业、南京健友等知名企业和上市公司成为基石投资者,但上市首日整体仍出现较大跌幅,股价或受到炒作概念影响。投资者需理性看待其业绩前景,警惕概念炒作的风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"68d519ec007bd04065c3224a9b78538f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 九源基因上市首日破发大跌38%,股价或受\"减肥神药\"概念炒作影响","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02566"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":94,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02566\",params:#limit:5,,,undefined,":[{"date":"2025-06-13","symbol":"02566","amount":0.056,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-16","defaultRemindTime":1749778200000,"name":"九源基因","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-06-16","currency":"CNY","dateTimestamp":1749744000000,"payDate":"2025-07-30"},{"date":"2025-03-26","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"","dateTimestamp":1742918400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02566\",market:\"HK\",,,undefined,":[{"executeDate":"2025-06-13","recordDate":"2025-06-16","paymentDate":"2025-07-30","value":0.056,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02566\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02566\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02566","date":"2025-05-09","current":10.406872,"percent":0.349515,"low":9.307514,"twenty":10.062805,"median":11.203375,"eighty":12.472285,"high":14.699674,"avg":11.376383,"sd":1.307767,"marketCap":1494478692},"quantilePoints":[{"date":"2024-12-06","current":14.097915,"twenty":14.208262,"median":14.275695,"eighty":14.595644,"marketCap":1946012484},{"date":"2024-12-13","current":13.217326,"twenty":13.348436,"median":13.95821,"eighty":14.334483,"marketCap":1820859096},{"date":"2024-12-20","current":12.20261,"twenty":12.40882,"median":13.381214,"eighty":14.243818,"marketCap":1673619816},{"date":"2024-12-27","current":12.158366,"twenty":12.254449,"median":13.1954,"eighty":14.180675,"marketCap":1666257852},{"date":"2025-01-03","current":11.126814,"twenty":12.0799,"median":12.46117,"eighty":14.042033,"marketCap":1526380536},{"date":"2025-01-10","current":9.714633,"twenty":11.141125,"median":12.29741,"eighty":13.763077,"marketCap":1327607508},{"date":"2025-01-17","current":9.904165,"twenty":10.518129,"median":12.180488,"eighty":13.509332,"marketCap":1354601376},{"date":"2025-01-24","current":10.07429,"twenty":9.9409,"median":12.04207,"eighty":13.348436,"marketCap":1386503220},{"date":"2025-01-28","current":10.358786,"twenty":9.995541,"median":11.819979,"eighty":13.282881,"marketCap":1433128992},{"date":"2025-02-07","current":11.238302,"twenty":10.0243,"median":11.162591,"eighty":13.191014,"marketCap":1546012440},{"date":"2025-02-14","current":11.154484,"twenty":10.062805,"median":11.126814,"eighty":12.776093,"marketCap":1533742500},{"date":"2025-02-21","current":12.73316,"twenty":10.073062,"median":11.193598,"eighty":12.735779,"marketCap":1757055408},{"date":"2025-02-28","current":11.508443,"twenty":10.189099,"median":11.508443,"eighty":12.653552,"marketCap":1582822260},{"date":"2025-03-07","current":12.084413,"twenty":10.276651,"median":11.554796,"eighty":12.584056,"marketCap":1668711840},{"date":"2025-03-14","current":12.91496,"twenty":10.28916,"median":11.611229,"eighty":12.584056,"marketCap":1784049276},{"date":"2025-03-21","current":12.244709,"twenty":10.311241,"median":11.810026,"eighty":12.735779,"marketCap":1690797732},{"date":"2025-03-28","current":11.696332,"twenty":10.344738,"median":11.831112,"eighty":12.72799,"marketCap":1734969516},{"date":"2025-04-03","current":10.807781,"twenty":10.395616,"median":11.800074,"eighty":12.674918,"marketCap":1600000176},{"date":"2025-04-11","current":9.828764,"twenty":10.27298,"median":11.65378,"eighty":12.589531,"marketCap":1445398932},{"date":"2025-04-17","current":9.988361,"twenty":10.075173,"median":11.569961,"eighty":12.56072,"marketCap":1472392800},{"date":"2025-04-25","current":10.079541,"twenty":10.050182,"median":11.463659,"eighty":12.511173,"marketCap":1487116728},{"date":"2025-05-02","current":10.290636,"twenty":10.067013,"median":11.287756,"eighty":12.494061,"marketCap":1467484824},{"date":"2025-05-09","current":10.406872,"twenty":10.062805,"median":11.203375,"eighty":12.472285,"marketCap":1494478692}],"updateTime":1746857042920}}}